<DOC>
	<DOCNO>NCT00657709</DOCNO>
	<brief_summary>The propose study aim assess immunogenicity , safety , tolerability lot lot consistency 3 lot Novartis Meningococcal B vaccine give concomitantly routine infant vaccine .</brief_summary>
	<brief_title>Immunogenicity , Safety Lot Lot Consistency Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis , Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Healthy 2month old infant ( 5589 day , inclusive ) Prior vaccination routine infant vaccine ( Diphtheria , Tetanus , Pertussis , Polio , Haemophilus influenzae type b ( Hib ) , Pneumococcal antigens ) Previous ascertain suspected disease cause N. meningitidis History severe allergic reaction previous vaccination hypersensitivity vaccine component ; Any serious chronic progressive disease Known suspect impairment alteration immune system</criteria>
	<gender>All</gender>
	<minimum_age>55 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>infant</keyword>
	<keyword>Meningococcal disease</keyword>
	<keyword>prevention</keyword>
	<keyword>vaccination</keyword>
</DOC>